<code id='642F21AED7'></code><style id='642F21AED7'></style>
    • <acronym id='642F21AED7'></acronym>
      <center id='642F21AED7'><center id='642F21AED7'><tfoot id='642F21AED7'></tfoot></center><abbr id='642F21AED7'><dir id='642F21AED7'><tfoot id='642F21AED7'></tfoot><noframes id='642F21AED7'>

    • <optgroup id='642F21AED7'><strike id='642F21AED7'><sup id='642F21AED7'></sup></strike><code id='642F21AED7'></code></optgroup>
        1. <b id='642F21AED7'><label id='642F21AED7'><select id='642F21AED7'><dt id='642F21AED7'><span id='642F21AED7'></span></dt></select></label></b><u id='642F21AED7'></u>
          <i id='642F21AED7'><strike id='642F21AED7'><tt id='642F21AED7'><pre id='642F21AED7'></pre></tt></strike></i>

          Home / hotspot / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:5219
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In